Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

Abstract

Background

Rituximab, a monoclonal antibody against the B-cell-specific surface protein CD20, is being evaluated for treatment of multiple sclerosis and neuromyelitis optica. Both diseases are restricted to the brain and cerebrospinal fluid (CSF). Whereas the ability of rituximab to deplete B cells in peripheral blood and tissue is well known, little information is available about the ability of rituximab to penetrate the barriers separating brain and CSF from the serum compartment.

Objective

To measure rituximab levels in serum and CSF of rituximab-treated patients and correlate them with CSF and response markers.

Methods

Fourteen paired serum/CSF samples of patients with autoimmune nervous system disorder were analyzed for up to 43 weeks after rituximab application.

Results

Rituximab remains detectable within the CSF after i.v. application for up to 24 weeks. Furthermore, levels of rituximab in CSF correlate significantly with the integrity of the blood CSF barrier.

Keywords

blood-CSF-barrier intrathecal Ig synthesis multiple sclerosis rituximab

Get full access to this article

View all access options for this article.

References

1 Cohen SB Emery P Greenwald MW . Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793–2806.

2 Stüve O Cepok S Elias B . Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005; 62: 1620–1623.

3 Petereit H Rubbert A . Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis. Arch Neurol 2005; 62: 1641–1642.

4 Cree BAC Lamb S Morgan K Chen A Waubant E Genain C . An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270–1272.

5 Petereit HF Moeller-Hartmann W Reske D Rubbert A . Rituximab in a patient with multiple sclerosis – effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2007; 117: 399–403.

6 Reiber H . External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based CSF/serum quotients. Clin Chem 1995; 41: 256–263.

7 Petereit HF Reske D Pukrop R . No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis. Mult Scler 2006; 12: 66–71.

8 Felgenhauer K . Theoretische Grundlagen einer Labordiagnostik neurologischer Erkrankungen. In: K Felgenhauer W Beuche , (eds), Labordiagnostik neurologischer Erkrankungen. Stuttgart: Georg Thieme Verlag; 1999. p. 3–12.

9 Ruhstaller TW Amsler U Cerny T . Rituximab: active treatment of central nervous system involvement by non-Hodgkin’s lymphoma. Ann Oncol 2000; 11: 374–375.

10.

10 Emery P Fleischmann RM Filipowicz-Sosnowska A . The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390–1400.

11.

11 Regazzi MB Iacona I Avanzini MA . Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogenous clinical settings. Ther Drug Monit 2005; 27: 785–792.